PATENT CLAIM ANALYSIS

Application Number: 15926076
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-09
Patent Classification: ["514", "220000"]

Abstract:
The disclosure is directed to methods of treating schizophrenia or bipolar disorder by subcutaneously administering a sustained-release dosage form of olanzapine, or a pharmaceutically acceptable salt thereof. Methods of subcutaneously administering olanzapine, or a pharmaceutically acceptable salt thereof, are also described.

Claim (Index 30):
The method of  claim 23 , wherein the pharmaceutical dosage form further comprises at least one biodegradable polymer.

Metadata:
- Claim Count in Document: 164.0
- Percentile: 90.0
- Lexical Diversity: 1.53333
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14995658', '15101874', '11274887', '14714621', '14773642']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7147476033643749
- 35 USC 102 Novelty (BERT): 0.5082923191602094
- Combined Prediction Score: 0.6941020749439584
- Mean Citation Score: 173.36240800000004
- Max Citation Score: 178.04628
- Similarity Product: 105.89150516663072

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test